Research Article

Postoperative Adjuvant Treatment Strategy for Locally Advanced Rectal Cancer after Neoadjuvant Treatment

Jia-yi Li, Xuan-zhang Huang, Peng Gao, Xiao-wan Chen, Yong-xi Song, Xing-er Lv, Yv Fu, Qiong Xiao, and Zhen-ning Wang

Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Affiliated Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang City 110001, China

Correspondence should be addressed to Zhen-ning Wang; josieon826@sina.cn

Received 24 September 2020; Revised 16 March 2021; Accepted 19 March 2021; Published 28 March 2021

Copyright © 2021 Jia-yi Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Neoadjuvant (chemo) radiotherapy is used as a standard treatment for locally advanced rectal cancer (LARC), but there is no general consensus on either the efficacy of postoperative adjuvant chemotherapy in patients with LARC after neoadjuvant treatment and surgery, or whether the addition of oxaliplatin to adjuvant chemotherapy provides survival benefits.

Methods. We performed a meta-analysis of data from the PubMed and Embase databases. We included patients with LARC who received neoadjuvant (chemo) radiotherapy and curative surgery. Overall survival (OS), disease-free survival (DFS), toxicity, and compliance were analyzed in the oxaliplatin/fluorouracil- (OX/FU-) based group compared with the FU-based group, and in the chemotherapy group compared with the observation group.

Results. Twenty studies were included in the analysis. Our results indicated that adjuvant chemotherapy prolonged OS (hazard ratio \( \text{HR} = 0.78, 95\% \text{CI} = 0.67 \text{–} 0.91 \)) in patients with LARC treated with neoadjuvant (chemo) radiotherapy and surgery compared with those in the observation group. Subgroup analysis showed the same results in both the ypStage II and ypStage III groups. Compared with those in the observation group, patients in the chemotherapy group also showed an increase in DFS (HR = 0.75, 95\% CI = 0.60 \text{–} 0.93). No significant increase was observed in OS (HR = 1.04, 95\% CI = 0.87 \text{–} 1.24) or DFS (HR = 0.98, 95\% CI = 0.76 \text{–} 1.27) when oxaliplatin was added to FU-based adjuvant chemotherapy, as compared with the FU-based treatment, and subgroup analysis also indicated no survival benefits in the clinical stage II, clinical stage III, ypStage II, and ypStage III groups. Conclusions. For patients with LARC who have already received neoadjuvant (chemo) radiotherapy and curative surgery, adjuvant chemotherapy improves OS over that in the observation group. Adding oxaliplatin to FU-based adjuvant chemotherapy does not confer survival benefits beyond those from FU-based adjuvant chemotherapy.

1. Introduction

Colorectal cancer is the second most frequent cancer in women and the third most frequent cancer in men [1]. To date, surgical resection is the main radical treatment. According to the NCCN guidelines, the standard treatment is postoperative adjuvant chemotherapy with or without oxaliplatin for patients with locally advanced rectal cancer (LARC) after neoadjuvant treatment [2]. However, according to the ESMO guidelines, the available evidence is insufficient for the use of postoperative chemotherapy after neoadjuvant chemoradiation [3]. Moreover, a consensus has not been reached on whether adjuvant chemotherapy should be used, and which specific chemotherapy regimens can be used after neoadjuvant treatment. Although some studies have demonstrated that adjuvant chemotherapy should be used for patients with LARC after neoadjuvant chemoradiation and surgery [4–8], the effects of adjuvant chemotherapy are unclear in patients with LARC receiving neoadjuvant chemoradiation.

An oxaliplatin-based adjuvant chemotherapy regimen for LARC patients who have received neoadjuvant treatment has been mainly extrapolated from results achieved with oxaliplatin-containing adjuvant chemotherapy in lymph
node-positive colon cancer patients [9, 10], a strategy that is also considered as an optional adjuvant chemotherapy for rectal cancer in the NCCN guidelines. However, whether oxaliplatin meaningfully affects the survival outcomes in patients with rectal cancer after neoadjuvant treatment remains unclear. In the German CAO/ARO/AIO-04 trial, the addition of oxaliplatin to adjuvant chemotherapy has been found to be beneficial in terms of disease-free survival (DFS) in patients with LARC after neoadjuvant chemoradiation with oxaliplatin as an additional radiosensitizer [11]. In the ADORE trial, oxaliplatin-based adjuvant chemotherapy was found to significantly increase DFS but not overall survival (OS) in patients with ypStage III rectal cancer [12]. However, the final results of the PETACC-6 trial, which added oxaliplatin to both neoadjuvant chemoradiation (as an radiosensitizer) and adjuvant chemotherapy, have indicated no survival benefits in patients with LARC receiving oxaliplatin/fluorouracil-based (OX/FU-based) adjuvant chemotherapy compared with FU-based adjuvant chemotherapy [13]. In addition, oxaliplatin inevitably results in toxicity, thus, leading to poor compliance in postoperative chemotherapy. In a random trial, more than 40% of the safety population who received neoadjuvant chemoradiation and subsequently at least one cycle of oxaliplatin-based adjuvant chemotherapy had grade 3/4 toxicity, and only 48.1% of patients completed all the planned cycles [14]. Therefore, the use of oxaliplatin should be comprehensively considered in terms of all aspects including efficacy, toxicity, and compliance. Regarding whether adjuvant chemotherapy should be used, although one study has reported that adjuvant chemotherapy improves OS among patients treated with neoadjuvant chemoradiation [15], some studies have found that adjuvant chemotherapy does not improve OS or DFS in patients with LARC [16]. Some trials have also indicated that adjuvant chemotherapy may be beneficial in ypStage III patients only but not in ypStage II LARC patients [12, 17]. Furthermore, for patients with rectal cancer downstaged to ypStage 0 or I after neoadjuvant chemoradiation, the survival benefits of adjuvant chemotherapy also remain unclear, although adjuvant chemotherapy is typically considered. Some studies have shown that adjuvant chemotherapy confers survival benefits to patients with ypStage 0 and ypT2N0M0 (ypStage I) [15, 18]; however, other studies have reported that adjuvant chemotherapy is not necessary for patients with rectal cancer achieving either ypStage 0 or ypStage I [19, 20]. Therefore, it is of great significance in clinical practice to explore whether the survival benefits of adjuvant chemotherapy are related to pathologic tumor stage after neoadjuvant treatment in rectal cancer.

In this meta-analysis, we sought to summarize and further assess the survival benefits of postoperative chemotherapy following neoadjuvant treatment and curative surgery for patients with LARC and examine the role of oxaliplatin in adjuvant chemotherapy.

2. Materials and Methods

This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines (Supplementary File 1) [21], and the Newcastle–Ottawa Scale (NOS) criteria were used to assess the methodological quality of the included studies [22].

2.1. Search Strategy. We performed an integrated search in PubMed and Embase until December 2019 using MeSH/main keywords of “neoadjuvant chemotherapy,” “neoadjuvant radiotherapy,” “neoadjuvant chemoradiotherapy,” “neoadjuvant treatment,” “neoadjuvant treatments,” “neoadjuvant therapy,” “neoadjuvant therapies,” “preoperative chemotherapy,” “preoperative radiotherapy,” “preoperative chemoradiotherapy,” “preoperative treatment,” “preoperative therapies,” “pre-operative chemotherapy,” “pre-operative radiotherapy,” “pre-operative chemoradiotherapy,” “pre-operative treatment,” “pre-operative treatments,” “pre-operative therapies,” “pre-operative chemotherapeutic drugs”, “neoadjuvant chemotherapy for LARC patients after neoadjuvant treatment,” and (v) the outcomes of studies included OS, DFS, toxicity, or compliance. Studies were excluded according to the following criteria: (i) studies of patients diagnosed with diseases other than rectal cancer; (ii) studies that compared preoperative (chemo) radiotherapy; (iii) all patients underwent surgical resection of rectal cancer; (iv) studies compared chemotherapy with observation or compared postoperative OX/FU-based chemotherapy with FU-based chemotherapy (OX/FU-based chemotherapy included 5-FU and leucovorin plus oxaliplatin [FOLFOX] or capecitabine plus oxaliplatin [CAPEOX] and FU-based chemotherapy included 5-FU alone or capcitabine alone, because capecitabine and 5-FU are homologous chemotherapeutic drugs and are recommended adjuvant chemotherapeutic drugs for LARC patients after neoadjuvant treatment); and (v) the outcomes of studies included OS, DFS, toxicity, or compliance. Studies were excluded according to the following criteria: (i) studies of patients diagnosed with diseases other than rectal cancer; (ii) studies of patients who did not receive preoperative (chemo) radiotherapy; (iii) studies that compared preoperative OX/FU-based therapy with preoperative FU-based therapy; (iv) reviews, meta-analyses, and case reports; and (v) studies without outcomes relevant to this analysis. Two reviewers assessed all studies independently, and the final selected studies were determined on the basis of agreement between the two reviewers.

2.2. Eligibility Criteria. The eligible studies met the following inclusion criteria: (i) patients were diagnosed with rectal cancer; (ii) all patients received preoperative (chemo) radiotherapy; (iii) all patients underwent surgical resection of rectal cancer; (iv) studies compared chemotherapy with observation or compared postoperative OX/FU-based chemotherapy with FU-based chemotherapy (OX/FU-based chemotherapy included 5-FU and leucovorin plus oxaliplatin [FOLFOX] or capecitabine plus oxaliplatin [CAPEOX] and FU-based chemotherapy included 5-FU alone or capcitabine alone, because capecitabine and 5-FU are homologous chemotherapeutic drugs and are recommended adjuvant chemotherapeutic drugs for LARC patients after neoadjuvant treatment); and (v) the outcomes of studies included OS, DFS, toxicity, or compliance.
adjuvant treatment regimen, type of surgery, median interval from surgery to adjuvant chemotherapy, and study outcomes including OS, DFS, compliance (completion of planned number of cycles), and toxicity (e.g., vomiting, nausea, neuropathy, allergic reaction, diarrhea, and hand-foot syndrome).

2.4. Statistical Analysis. The primary endpoints were DFS and OS. The secondary endpoints were compliance and toxicity. We evaluated the primary endpoint with the hazard ratio (HR) and 95% confidence interval (CI). Then, we calculated the pooled risk ratio (RR) with 95% CI to assess toxicity. If a study did not provide the HR or 95% CI directly, we used published data to obtain the statistics by using the methods reported by Tierney et al. [23].

We analyzed the overall OS and DFS for the OX/FU-based group versus the FU-based group, and the chemotherapy group versus the observation group. Additionally, we conducted subgroup analysis according to study design, pathologic tumor stage after neoadjuvant treatment (ypTNM), preoperative clinical tumor stage (cTNM), and neoadjuvant treatment regimen. Statistical analysis of compliance and toxicity was performed on the basis of data from the studies. According to the heterogeneity, we used a random-effects model when $I^2 > 50\%$ or $p < 0.1$; otherwise, we used a fixed-effects model [24]. Publication bias was assessed with funnel plots with Begg’s and Egger’s tests [25, 26]. Findings were considered significant with a two-sided $p$ value ≤ 0.05.

All analyses were performed in Stata software, version 12.0 (2011; Stata Corp., College Station, TX, USA).

3. Results

3.1. Study Research. A total of 4741 studies were retrieved by the electronic search in total (977 studies were from PubMed, and 3764 studies were from Embase). A total of 4067 studies remained after the elimination of duplicates. Subsequently, 3914 articles were removed on the basis of the eligibility criteria according to the titles and abstracts, after which 153 articles were retained. After further reading and evaluation of the full text, 20 studies were ultimately included in this meta-analysis, including seven randomized controlled trials (RCTs) and 13 non-RCTs (nRCTs) [4–6, 8, 11–16, 27–36]. The detailed research steps are shown in Figure 1.

3.2. Characteristics of Included Studies. Twenty studies on 30662 patients were enrolled in the meta-analysis. Among the included studies, eight were from Europe, four from the USA, three from China, three from Korea, one from Canada, and one from Israel. Regarding the interventions, four studies had two arms containing an OX/FU-based group and FU-based group, 13 studies contained a chemotherapy group and observation group, and the other three studies contained an OX/FU-based group, FU-based group, and observation group. In terms of the neoadjuvant treatment regimen, preoperative long-course radiation with chemotherapy was conducted in 18 studies, long-course radiation alone or with chemotherapy was conducted in one study, and short-course radiation alone or with chemotherapy was used in one study. The follow-up duration of most studies was more than 3 years, four studies had longer durations of more than 5 years, and only two studies had durations of less than 1 year.
| Study          | Country and year | Study design | No. of patients (M/F) | Arm | Age mean ± SD /median (range) | Follow-up mean ± SD/median (range) | T category (0-2/3/4/NR) | N category (N-/N+/NR) | TNM stage (0-I/II/III/IV/NR) | Type of neoadjuvant chemotherapy | Type of adjuvant chemotherapy NOS |
|---------------|------------------|--------------|-----------------------|-----|-----------------------------|-----------------------------------|--------------------------|------------------------|-------------------------------|---------------------------------|----------------------------------|
| Javier Sastre | Spain 2016       | nRCT         | 87 (50/37)            | OX  | 69 (35-86)                  | NR                                | ypT3-4: 50               | yp: -/50/-               | NR                            | 5.4 Gy boost + 45 Gy/25F , CAP+5-FU or UFT | FOLFOX or XELOX                   |
| Rodel         | German 2015      | RCT          | 1236 (874/362)        | OX  | Median: 64                  | 50 (38–61)                        | ypT0-2: 37               | yp: 37/-                 | yp: 252/154/154/201/16     | 50.4 Gy/28F, FU+ oxaliplatin  | FU + oxaliplatin                  |
| Hong, Y. S.  | Korea 2019       | RCT          | 321 (234/87)          | OX  | 54 (25-79)                  | 74.1 (56.2-88.0)                 | yp: 416/175/5           | yp: 423/191/1            | yp: 257/148/169/35/6       | 50.4 Gy/28F, FU                  | FU                               |
| Chung, M. J. *| Korea 2019       | nRCT         | 1442 (975/467)        | OX  | NR                          | 48.8 (6.5-141.0)                 | yp: 13/55/-             | yp: 37/1677             | 5 – FU + LV + oxaliplatin   | 5 – FU + LV                      |                                  |
| Loree, J. M. | Canada 2018      | nRCT         | 485 (343/142)         | OX  | 61 (52-68)                  | Median: 5.1y                    | ypT0-2: 10, ypT3-4: 58  | yp: 13/55/-             | yp: 134/48/-              | 45 to 54 Gy, 5-FU or CAP or FOLFOX or I XO |                                  |
| Christian     | Germany 2016     | nRCT         | 1497 (1006/490)       | OX  | 65 (29.0–88.0)              | Median: 38                       | ypT0-2: 10, ypT3-4: 58  | yp: 13/55/-             | yp: 134/48/-              | 5 – FU + LV                     |                                  |
| Peng, J. H.  | China 2018       | nRCT         | 105 (70/35)           | CT  | 51.3 ± 11.4                 | c: 4/45/24/5                  | yp: /208/28/17/1         | c: /435/134/-           | 5FU-only-based CRT          | 5-FU or FA or CAP               |                                  |
| UK            | RCT              | 113 (30/83)   | OB  | 58.0 (52.0–65.0)            | Median: 44.8                    | yp: 25/27/2/-               | yp: 44/10/-             | yp: 44/10/-             | XELOX                         |                                  |
| You, K. Y.   | China 2014       | nRCT         | 160 (119/41)          | CT  | 54 (15-80)                  | Median: 47                     | yp: /208/28/17/1         | c: /435/134/-           | 5FU-based CRT              |                                  |
| USA           | RCT              | 12696 (7853/4843) | OB  | 56.0 (48-64)                | NR                               | yp: /156/24/37/-         | Chemoradiation          | NR                            | 45 Gy/28F, 5-FU + FA         | 5-FU + FA                        |
| Study                  | Country and year | Study design | No. of patients (M/F) | Age mean ± SD /median (range) | Follow-up mean ± SD/median (range) | T category (0-2/3/4/NR) | N category (N-/N+ /NR) | TNM stage (0-I/II/III/IV/NR) | Type of neoadjuvant chemotherapy | Type of adjuvant chemotherapy | NOS |
|-----------------------|------------------|--------------|-----------------------|--------------------------------|-----------------------------------|-------------------------|------------------------|----------------------------------|---------------------------------|---------------------------------|-----|
| Sainato, A.           | USA nRCT 2017 (5212/3132) OB | 634 (421/213) | OB Mean: 60.6 Median: 63.7 m | ypT0-2: 150, ypT3-4: 143, ypTx: 3 | c: 168/112/44          | 164/1527/44 | 194/76/40 | yp: 1823/2349/1- | Chemoradiation |                    |     |
| Kulaylat, A. S.       | USA nRCT 2017 (164/95) OB | 8344 CT NR NR NR | 56.67 ± 13.04 Mean: 61.88 ± 11.31 | 38 (26-56) w c: 11/93/9/1 | 36 (23-56) w c: 33/81/- | c: -/1869/2303/- | c: -/1869/2303/- | NR | Chemoradiation |                    |     |
| Kuan, F. C.           | China nRCT 2017 (164/95) OB | 259 CT NR NR NR | 55.6 ± 11.8 Mean: 59.4 ± 12.1 | 51.2 (25.8-68.1) m | 51.4 (34.7-78.2) m | 29/28/1/- | yrp: 48/22/-/1 | NR | Chemoradiation |                    |     |
| Kiran, R. P.          | USA nRCT 2012 (90/38) OB | 128 CT NR NR NR | 54.0 (46.5-62.5) Mean: 41.0 ± 7.0 | 217/206/18/- | yp: 301/140/- | 182/118/141/- | NR | Chemoradiation |                    |     |
| Jung, K. U.           | Korea nRCT 2015 (312/164) OB | 476 CT NR NR NR | 64.0 (47.0-72.0) Mean: 42.1 m | 17/17/1/- | yp: 23/12/- | 17/6/12/- | NR | Chemoradiation |                    |     |
| Geva, R               | Israel nRCT 2014 (32/20) OB | 52 CT 60.9 ± 11.9 Mean: 68.4 ± 43.4 m | 1/31/-/3 | 23/9/3 | c: 32/1/3/2 | 12/3/2 | 25Gy/5F or 45-50Gy/25F, 5-FU | NR | Chemoradiation |                    |     |
| Breugom, A. J.        | Netherlands RCT 2015 (270/167) OB | 437 CT NR NR NR | Median: 61.13 ± 8.94 Mean: 61.08 ± 9.13 | 5.0 (0.02-13.12) y | NR | -39/177/-/1 | 25Gy/5F or 45-50Gy/25F, 5-FU | NR | Chemoradiation |                    |     |
| Bosset, J. F.         | France RCT 2014 (739/272) OB | 1011 CT NR NR | 10.4 (7.8-13.1) y | c: -/454/52/- | -52/140/154 | 45 Gy/25F, 45 Gy/25F, 5-FU | FU + LV | Chemoradiation |                    |     |
| Ahn, D. H.            | USA nRCT 2017 (68/42) OB | 110 CT 54.3 (27-76) Mean: 38/1/-/1 | 68/-/3/3 | p: 37/28/6 | -/29/7/3 | 45-50.4 Gy, CAP or CAP + OX | CAP + OX | Chemoradiation |                    |     |
| Hoheinz, R. D.        | Germany RCT 2017 (68/42) OB | 1069 OX NR NR | Median: 31 m Mean: 31 m | 38/-/1 | p: 29/7/3 | 45-50.4 Gy, CAP or CAP + OX | CAP + OX | Chemoradiation |                    |     |

*Patient characteristics based on T category and N category were after propensity-score matching. RCT: randomized controlled trial; nRCT: nonrandomized controlled trial; M/F: male/female; OX: oxaliplatin-based group; FL: fluorouracil-based group; OB: observation group; CT: chemotherapy group; m: month; y: year; w: week; c: clinical stage; yp: pathologic stage after receiving neoadjuvant chemotherapy; p: pathologic stage; FU: fluorouracil; UFT: uracil + tegafur + fluorouracil; LV: leucovorin; CAP: capecitabine; FA: folinic acid; FOLFOX: fluorouracil + leucovorin + oxaliplatin; XELOX: capecitabine + oxaliplatin; CAPOX: capecitabine + oxaliplatin; IXO: irinotecan + capecitabine + oxaliplatin; "/" there is no relevant data; NR: not reported; NOS: Newcastle–Ottawa Scale criteria.
Figure 2: Continued.
year. The detailed baseline characteristics and study quality of the included studies are listed in Table 1.

3.3. Disease-Free Survival. According to our analyses, DFS did not significantly differ in the OX/FU-based group and the FU-based group (HR = 0.98, 95%CI = 0.76 – 1.27, p = 0.906, Figure 2(a)). To clarify the effect of the neoadjuvant treatment regimen on survival outcomes, we conducted a subgroup analysis based on the neoadjuvant treatment regi-

| Study             | ES (95% CI) | Weight % |
|-------------------|------------|----------|
| Chung, M. J.      | 0.63 (0.33, 1.18) | 4.64     |
| Loree, J. M.      | 0.93 (0.58, 1.50) | 7.14     |
| Peng, I. H.       | 0.30 (0.07, 1.33) | 1.05     |
| Glynne–Jones, R.  | 1.18 (0.43, 3.26) | 2.10     |
| You, K. Y.        | 0.68 (0.21, 2.24) | 1.58     |
| Sun, Z.           | 0.81 (0.72, 0.91) | 19.51    |
| Sainato, A.       | 1.05 (0.78, 1.41) | 12.16    |
| Kulaylat, A. S.   | 0.67 (0.59, 0.75) | 19.41    |
| Kuan, F. C.       | 0.72 (0.27, 1.93) | 2.22     |
| Kiran, R. P.      | 0.58 (0.11, 3.06) | 0.83     |
| Jung, K. U.       | 0.14 (0.03, 0.75) | 0.88     |
| Geva, R.          | 0.24 (0.04, 1.37) | 0.74     |
| Breugom, A. J.    | 0.93 (0.62, 1.39) | 8.79     |
| Bossut, J. F.     | 0.91 (0.77, 1.09) | 17.20    |
| Ahn, D. H.        | 0.18 (0.06, 0.57) | 1.74     |
| Overall (I–squared = 53.7%, p = 0.007) | 0.78 (0.67, 0.91) | 100.00  |

| Study          | ES (95% CI) | Weight % |
|----------------|------------|----------|
| Rodel          | 0.96 (0.72, 1.26) | 39.91    |
| Hong, Y. S.    | 0.73 (0.45, 1.19) | 13.22    |
| Loree, J. M.   | 1.67 (0.75, 3.73) | 4.86     |
| Hofheinz, R. D.| 1.19 (0.91, 1.57) | 42.02    |
| Overall (I–squared = 35.2%, p = 0.201) | 1.04 (0.87, 1.24) | 100.00  |

Figure 2: Forest plot based on survival outcomes. (a) Disease-free survival (DFS) in oxaliplatin/fluorouracil- (OX/FU-) based group versus fluorouracil- (FU-) based group; (b) DFS in chemotherapy group versus observation group; (c) overall survival (OS) in chemotherapy group versus observation group; (d) OS in OX/FU-based group versus FU-based group.
Overall ($I^2 = 64.0\%, p = 0.016$)

| Study                  | ES (95% CI)       | Weight % |
|------------------------|-------------------|----------|
| Javier Sastre          | 2.05 (1.02, 4.09) | 9.44     |
| Rodel                  | 0.79 (0.64, 0.98) | 24.92    |
| Hong, Y. S.            | 0.63 (0.43, 0.93) | 17.95    |
| Loree, J. M.           | 1.41 (0.67, 2.97) | 8.56     |
| Garlipp, B.            | 1.18 (0.73, 1.92) | 14.59    |
| Hofheinz, R. D.        | 1.02 (0.82, 1.28) | 24.53    |
| Overall ($I^2 = 64.0\%, p = 0.016$) | 0.98 (0.76, 1.27) | 100.00   |

Figure 3: Continued.
preoperative FU-based chemotherapy was used as a radiosensitizer in the long-course chemoradiation (HR = 1.10, 95% CI = 0.57 – 2.10, p = 0.782, Figure 3(b)). However, we were unable to evaluate the survival benefits in the OX/FU-based group versus the FU-based group in the patients treated with preoperative short-course radiotherapy alone or long-course chemoradiation with preoperative OX/FU-based chemotherapy as a radiosensitizer, owing to insufficient data. Moreover, the subgroup analysis based on ypN indicated no difference in DFS between the OX/FU-based group and FU-based group in both ypN− and ypN+ patients (ypN0: HR = 0.83, 95%CI = 0.64 – 1.08, p = 0.160; ypN1: HR = 1.05, 95%CI = 0.52 – 2.10, p = 0.897; ypN2: HR = 0.75, 95%CI = 0.33 – 1.70, p = 0.492). To investigate the specific patient group that would benefit from adding oxaliplatin to adjuvant chemotherapy, we further conducted a subgroup analysis based on ypStage. The OX/FU-based group did not show an increase in DFS over that in the FU-based group in either the ypStage II or ypStage III groups (ypStage II: HR = 0.82, 95%CI = 0.59 – 1.13, p = 0.225, Figure 4(a); ypStage III: HR = 0.74, 95%CI = 0.50 – 1.11, p = 0.142, Figure 4(b)). However, we could not evaluate the survival benefits of OX/FU-based versus FU-based adjuvant chemotherapy in ypStage I or ypStage 0, owing to insufficient data. In addition to pathologic tumor
Overall ($I^2 = 25.4\%, p = 0.262$)

| Study          | ES (95% CI) | Weight % |
|----------------|-------------|----------|
| Rodel          | 0.74 (0.49, 1.13) | 61.71    |
| Hong, Y. S.    | 0.64 (0.30, 1.36) | 18.86    |
| Loree, J. M.   | 1.41 (0.67, 2.97) | 19.43    |
| Overall ($I^2 = 25.4\%, p = 0.262$) | 0.82 (0.59, 1.13) | 100.00   |

Study of (a)

Overall ($I^2 = 50.5\%, p = 0.155$)

| Study          | ES (95% CI) | Weight % |
|----------------|-------------|----------|
| Rodel          | 0.89 (0.63, 1.28) | 55.38    |
| Hong, Y. S.    | 0.59 (0.38, 0.92) | 44.62    |
| Overall ($I^2 = 50.5\%, p = 0.155$) | 0.74 (0.50, 1.11) | 100.00   |

Study of (b)

Overall ($I^2 = 100.0\%$, $p = .)$

| Study          | ES (95% CI) | Weight % |
|----------------|-------------|----------|
| Hofheinz, R. D.| 0.95 (0.59, 1.51) | 100.00   |
| Overall ($I^2 = 100.0\%$, $p = .$) | 0.95 (0.59, 1.52) | 100.00   |

Study of (c)

Figure 4: Continued.
stage, the clinical tumor stage is an important factor used to define the guidelines for recommendation of administration of adjuvant chemotherapy; thus, we also conducted further subgroup analysis based on the clinical tumor stage, and the results also showed that DFS was not significantly different between the OX/FU-based group and FU-based group in both clinical stage II and III subpopulation (clinical stage II: HR = 0.95, 95%CI = 0.59 – 1.52, p = 0.831, Figure 4(c)); clinical stage III: HR = 1.09, 95%CI = 0.84 – 1.41, p = 0.533, Figure 4(d)).

Patients treated with adjuvant chemotherapy showed improved DFS over that in the observation group (HR = 0.75, 95%CI = 0.60 – 0.93, p = 0.008, Figure 2(b)), and subgroup analysis based on the neoadjuvant treatment regimen showed similar results in the subgroup of patients receiving preoperative long-course chemoradiation (HR = 0.69, 95%CI = 0.51 – 0.94, p = 0.018, Figure 3(c)). Furthermore, a longer DFS was observed in patients receiving chemotherapy than in patients in the observation group when patients were treated with preoperative radiotherapy and preoperative OX/FU-based chemotherapy as a radiosensitizer (HR = 0.41, 95%CI = 0.21 – 0.78, p = 0.007, Figure 3(d)). Although preoperative neoadjuvant radiotherapy may affect the survival benefits of adjuvant treatment in patients with rectal cancer, there were insufficient data to conduct a corresponding subgroup analysis. In an RCT of 473 rectal cancer patients, 86% of the patients who received preoperative short-course radiotherapy and 14% of patients who received preoperative long-course chemoradiation were randomly assigned to a chemotherapy group and observation group, and the results showed a similar 5-year DFS in the chemotherapy group versus the observation group (62.7% versus 55.4%) [35]. However, there were no sufficient data to support other subgroup analyses. The detailed results are shown in Table 2.

3.4. Overall Survival. Our results indicated a significantly increased OS in patients receiving chemotherapy (HR = 0.78, 95%CI = 0.67 – 0.91, p = 0.002, Figure 2(c)) compared with individuals in the observation group. However, a clear difference in OS was not found between the OX/FU-based group and FU-based group (HR = 1.04, 95% CI = 0.87 – 1.24, p = 0.656, Figure 2(d)). Subgroup analyses based on long-course neoadjuvant chemoradiation strategy showed similar results to the overall analysis. Increased OS was observed in the chemotherapy group versus the observation group (HR = 0.73, 95%CI = 0.61 – 0.89, p = 0.001, Figure 5(a)), and adding oxaliplatin to FU-based adjuvant chemotherapy was not beneficial for OS, as compared with that in the FU-based group (HR = 1.04, 95%CI = 0.87 – 1.24, p = 0.656, Figure 5(b)). Moreover, a tendency toward increased OS was found in the comparison between the chemotherapy group and observation group for patients receiving preoperative radiotherapy and preoperative OX/FU-based chemotherapy as a radiosensitizer (HR = 0.49, 95%CI = 0.20 – 1.24, p = 0.133, Figure 5(c)). However, the effects of different neoadjuvant chemotherapy strategies on survival benefits could not be evaluated in the comparison between the OX/FU-based group and FU-based group, owing to insufficient data. For preoperative short-course radiotherapy, in the RCT in which most rectal cancer patients (86% patients) treated with preoperative short-course radiotherapy alone, the survival rates in the adjuvant chemotherapy group and observation group were similar (80.4% vs. 79.2%), and no significant increase in OS was observed with adjuvant chemotherapy compared with observation (HR = 0.93, 95%CI = 0.62 – 1.39, p = 0.73) [35].

Moreover, in a comparison between adjuvant chemotherapy and observation, subgroup analysis based on ypN showed that ypN- patients who received adjuvant chemotherapy had better OS than those in the observation group (ypN+: HR = 0.66, 95%CI = 0.59 – 0.75, p < 0.001; ypN+: not applicable, owing to insufficient data). Further analysis based on ypStage showed that adjuvant chemotherapy contributed to better OS in both the ypStage I group and ypStage III (ypStage II: HR = 0.73, 95%CI = 0.60 – 0.88, p = 0.001, Figure 6(a); ypStage III: HR = 0.78, 95%CI = 0.65 – 0.95, p = 0.011, Figure 6(b)), but the data were insufficient for subgroup analysis in patients with ypStage 0 and ypStage I. In contrast, in the comparison between the OX/FU-based

| Study                     | ES (95% CI)     | Weight % |
|--------------------------|-----------------|----------|
| Hofheinz, R. D.          | 1.04 (0.79, 1.36)| 91.74    |
| Loree, J. M.             | 1.76 (0.71, 4.34)| 8.26     |
| Overall (I–squared = 16.0%, p = 0.275) | 1.09 (0.84, 1.41) | 100.00   |

Figure 4: Forest plot based on disease-free survival and tumor stage. (a) DFS in OX/FU-based group versus FU-based group in patients with ypStage II; (b) DFS in OX/FU-based group versus FU-based group in patients with ypStage III; (c) DFS in OX/FU-based group versus FU-based group in patients with clinical stage II; (d) DFS in OX/FU-based group versus FU-based group in patients with clinical stage III.
Table 2: Subgroup analysis of overall survival and disease-free survival.

| Subgroup | No. of study | HR  | 95% CI | OS P for HR | Heterogeneity (P, I²) | No. of study | HR  | 95% CI | DFS P for HR | Heterogeneity (P, I²) |
|----------|--------------|-----|--------|-------------|------------------------|--------------|-----|--------|--------------|------------------------|
| **Study design** | | | | | | | | | | | |
| RCT | 3 | 1.02 | 0.85-1.22 | 0.863 | 0.199, 38.0% | / | / | / | / | / |
| nRCT | 1 | 1.67 | 0.75-3.72 | 0.210 | / | / | / | / | / | / |
| **Neoadjuvant treatment regimen** | | | | | | | | | | | |
| Chemoradiation | 4 | 1.04 | 0.87-1.24 | 0.656 | 0.201, 35.2% | 6 | 0.99 | 0.76-1.27 | 0.906 | 0.016, 64.0% |
| RT + FU | / | / | / | / | / | 3 | 1.10 | 0.57-2.10 | 0.782 | 0.007, 79.6% |
| ypStage | | | | | | | | | | | |
| ypStage II | 2 | 1.24 | 0.68-2.27 | 0.491 | 0.263, 20.1% | 3 | 0.82 | 0.59-1.13 | 0.225 | 0.262, 25.4% |
| ypStage III | 1 | 0.72 | 0.41-1.26 | 0.248 | / | 2 | 0.74 | 0.50-1.11 | 0.142 | 0.155, 50.5% |
| Clinical stage | | | | | | | | | | | |
| Clinical stage II | 2 | 1.07 | 0.65-1.75 | 0.793 | 0.299, 7.3% | 1 | 0.95 | 0.59-1.52 | 0.831 | / |
| Clinical stage III | 2 | 1.25 | 0.90-1.72 | 0.183 | 0.561, 0.0% | 2 | 1.09 | 0.84-1.41 | 0.533 | 0.275, 16.0% |
| ypN | | | | | | | | | | | |
| ypN0 | 2 | 1.26 | 0.68-2.36 | 0.466 | 0.275, 16.1% | 3 | 0.83 | 0.64-1.08 | 0.16 | 0.316, 13.2% |
| ypN1 | 2 | 1.05 | 0.54-2.05 | 0.888 | 0.474, 0.0% | 2 | 1.05 | 0.52-2.10 | 0.897 | 0.411, 0.0% |
| ypN2 | 1 | 0.42 | 0.18-0.97 | 0.042 | / | 2 | 0.75 | 0.33-1.70 | 0.492 | 0.070, 69.5% |
| **Chemotherapy group versus observation group** | | | | | | | | | | | |
| Chemoradiation | 13 | 0.73 | 0.61-0.89 | 0.001 | 0.013, 52.8% | 10 | 0.69 | 0.51-0.94 | 0.018 | 0.002, 65.8% |
| RT + OX | 2 | 0.49 | 0.20-1.24 | 0.133 | 0.396, 0.0% | 2 | 0.41 | 0.21-0.78 | 0.007 | 0.437, 0.0% |
| ypStage | | | | | | | | | | | |
| ypStage II | 3 | 0.73 | 0.60-0.88 | 0.001 | 0.481, 0.0% | 2 | 0.57 | 0.16-2.11 | 0.401 | 0.113, 60.2% |
| ypStage III | 2 | 0.78 | 0.65-0.95 | 0.011 | 0.126, 57.2% | / | / | / | / | / |
| ypN | | | | | | | | | | | |
| ypN0 | 7 | 0.66 | 0.59-0.75 | <0.001 | 0.013, 52.8% | 10 | 0.69 | 0.51-0.94 | 0.018 | 0.002, 65.8% |

RCT: randomized controlled trial; nRCT: nonrandomized controlled trial; RT: radiotherapy; OX: oxaliplatin-based chemotherapy; FU: fluorouracil-based chemotherapy; OS: overall survival; DFS: disease-free survival; HR: hazard ratio; CI: confidence interval; I²: degree of heterogeneity; ypStage: pathologic stage after receiving neoadjuvant chemotherapy; "/": there is no relevant data.
Figure 5: Forest plot based on overall survival after neoadjuvant chemoradiation. (a) Chemotherapy group versus observation group; (b) OX/FU-based group versus FU-based group; (c) chemotherapy group versus observation group after preoperative OX/FU-based chemoradiation.
### Figure 6: Continued.

| Study               | ES (95% CI)               | Weight % |
|---------------------|---------------------------|----------|
| Loree, J. M.        | 0.93 (0.58, 1.50)         | 16.25    |
| You, K. Y.         | 0.48 (0.11, 2.06)         | 1.71     |
| Sun, Z.             | 0.70 (0.57, 0.87)         | 82.04    |
| Overall (I-squared = 0.0%, \(p = 0.481\)) | 0.73 (0.60, 0.88) | 100.00 |

(a)

| Study               | ES (95% CI)               | Weight % |
|---------------------|---------------------------|----------|
| Sun, Z.             | 0.85 (0.74, 0.98)         | 57.79    |
| Kulaylat, A. S.     | 0.70 (0.57, 0.86)         | 42.21    |
| Overall (I-squared = 57.2%, \(p = 0.126\)) | 0.78 (0.65, 0.95) | 100.00 |

(b)

| Study               | ES (95% CI)               | Weight % |
|---------------------|---------------------------|----------|
| Hong, Y. S.        | 0.83 (0.33, 2.10)         | 42.90    |
| Loree, J. M.       | 1.67 (0.75, 3.73)         | 57.10    |
| Overall (I-squared = 20.1%, \(p = 0.263\)) | 1.24 (0.67, 2.27) | 100.00 |

(c)
group and FU-based group, no OS benefit was observed in patients with either the ypN0 group or ypN+ group (ypN0: HR = 1.26, 95% CI = 0.68 – 2.36, p = 0.466; ypN1: HR = 1.05, 95% CI = 0.54 – 2.05; ypN2: HR = 0.42, 95% CI = 0.18 – 0.97, p = 0.042), and similar results were also found in further analysis based on ypStage (ypStage II: HR = 1.24, 95% CI = 0.67 – 2.27, p = 0.491, Figure 6(c); ypStage III: HR = 0.72, 95% CI = 0.41 – 1.26, Figure 6(d)). Similarly, no OS differences were observed in both clinical stage II and III subpopulations (clinical stage II: HR = 1.07, 95% CI = 0.65 – 1.75, p = 0.793, Figure 6(e); clinical stage III: HR = 1.25, 95% CI = 0.90 – 1.72, p = 0.183, Figure 6(f)).

In the chemotherapy group versus the observation group, nRCTs indicated a significant difference in OS, whereas RCTs showed a limited clinical benefit in terms of OS after adjuvant chemotherapy, and the results were not statistically

| Study             | ES (95% CI) | Weight % |
|-------------------|-------------|----------|
| Hong, Y. S.       | 0.72 (0.41, 1.25) | 100.00   |
| Overall (I−squared = 100.0%, p = .) | 0.72 (0.41, 1.26) | 100.00   |
| Hofheinz, R. D.   | 0.95 (0.55, 1.63) | 83.26    |
| Loree, J. M.      | 1.92 (0.57, 6.43) | 16.74    |
| Overall (I−squared = 7.3%, p = 0.299) | 1.07 (0.65, 1.75) | 100.00   |
| Hofheinz, R. D.   | 1.21 (0.86, 1.69) | 91.60    |
| Loree, J. M.      | 1.71 (0.56, 5.21) | 8.40     |
| Overall (I−squared = 0.0%, p = 0.561) | 1.25 (0.90, 1.72) | 100.00   |

**Figure 6:** Forest plot based on overall survival and tumor stage. (a) OS in chemotherapy group versus observation group in patients with ypStage II; (b) OS in chemotherapy group versus observation group in patients with ypStage III; (c) OS in OX/FU-based group versus FU-based group in patients with ypStage II; (d) OS in OX/FU-based group versus FU-based group in patients with ypStage III; (e) OS in OX/FU-based group versus FU-based group in patients with clinical stage II; (f) OS in OX/FU-based group versus FU-based group in patients with clinical stage III.
Figure 7: Forest plots for the incidence of (a) neuropathy, (b) allergic reaction, (c) vomiting, and (d) nausea in the oxaliplatin/fluorouracil-based group compared with fluorouracil-based group.
significant (HR = 0.73, 95% CI = 0.67–0.79, p < 0.001; HR = 0.95, 95% CI = 0.82–1.09, p = 0.437). In OX/FU-based chemotherapy versus FU-based chemotherapy, there was no benefit in either RCTs or nRCTs when oxaliplatin was added (HR = 1.02, 95% CI = 0.85–1.22, p = 0.863; HR = 1.67, 95% CI = 0.75–3.72, p = 0.210). The details are shown in Table 2.

3.5. Toxicity. Our overall analyses demonstrated that the OX/FU-based group showed a significantly greater incidence of neuropathy (RR = 6.47, 95% CI = 5.07–8.24; p < 0.001, Figure 7(a)), allergic reaction (RR = 3.23, 95% CI = 1.85–5.64; p < 0.001, Figure 7(b)), vomiting (RR = 2.55, 95% CI = 1.86–3.50; p < 0.001, Figure 7(c)), and nausea (RR = 1.58, 95% CI = 1.33–1.87; p < 0.001, Figure 7(d)) than the FU-based group. In the OX/FU-based group versus the FU-based group, the incidence rates of neuropathy, allergic reaction, vomiting, and nausea were 23.5% (95% CI = 21.6%–25.4%) vs. 3.6% (95% CI = 2.8%–4.5%), 4.6% (95% CI = 3.4%–5.9%) vs. 1.4% (95% CI = 0.7%–2.1%), 11.1% (95% CI = 9.3%–12.9%) vs. 4.3% (95% CI = 3.1%–5.5%), and 25.1% (95% CI = 22.5%–27.7%) vs. 16.0% (95% CI = 13.8%–18.2%), respectively. In the chemotherapy group versus the observation group, toxicity occurred only in patients receiving adjuvant chemotherapy, and we calculated the incidence rate of grade 3–4 toxicity. The rates of diarrhea, neuropathy, nausea, hand-foot syndrome, and vomiting were 17.0% (95% CI = 11.2%–22.7%), 5.5% (95% CI = 2.0%–8.9%), 5.5% (95% CI = 2.0%–8.9%), 3.6% (95% CI = 0.8%–6.5%), and 3.6% (95% CI = 0.8%–6.5%), respectively. The detailed results of subgroup analyses of toxicity are shown in Figure 7.

3.6. Compliance. For the OX/FU-based group and FU-based group, only two studies reported compliance. According to our meta-analysis results, the compliance with OX/FU-based...
chemotherapy was comparable to that with FU-based chemotherapy, with low heterogeneity (RR = 0.99, 95% CI = 0.94 – 1.03, p = 0.590, Figure 8(a)). Only one study reported that dose reduction was more common in the OX/FU-based group than in the FU-based group (135 of 445, 30% vs. 55 of 470, 12%; RR = 2.59, 95% CI = 1.95 – 3.45, Figure 8(b)) [11]. Moreover, only one study indicated that cycles with reduced doses were more common in the OX/FU-based group than in the FU-based group (430 of 1153, 37.3% vs. 102 of 580, 17.6%; RR = 2.12, 95% CI = 1.75 – 2.57, Figure 8(c)) [12].

4. Discussion

In this analysis, we included 20 studies on 30662 patients. In the chemotherapy group versus the observation group, adjuvant treatment was found to be beneficial in terms of OS and DFS. Subgroup analysis based on neoadjuvant treatment strategy revealed similar results, in which the adjuvant chemotherapy group showed higher OS and DFS than those in the observation group in patients treated with preoperative long-course chemoradiation. In addition, the results showed an increase in OS in either ypStage II or ypStage III in the chemotherapy group versus the observation group. In the OX/FU-based group, compared with the FU-based group, the addition of oxaliplatin did not contribute to OS or DFS. The results were also demonstrated in the subgroup analysis of patients treated with neoadjuvant long-course chemoradiation, and there were no significant survival benefits in the clinical stage II, clinical stage III, ypStage II, and ypStage III groups. However, oxaliplatin clearly increased the incidence of neuropathy, allergic reaction, vomiting, and nausea. Regarding compliance in completing all adjuvant chemotherapy cycles, there was no significant difference in the OX/FU-based group versus the FU-based group. However, the OX/FU-based group had a much higher rate of dose reduction than the FU-based group.

It has been reported that patients with ypStage III can benefit from adjuvant chemotherapy [5, 6], which is in agreement with the present results. Regarding patients with ypStage II who received neoadjuvant treatment, one study has shown no increase in OS or DFS [29], whereas other studies have indicated that patients with ypStage II benefit from adjuvant chemotherapy [5, 6]. Present pooled analysis showed that adjuvant chemotherapy improved OS in ypStage II patients undergoing neoadjuvant treatment and surgery. Several potential explanations may account for the survival benefits from adjuvant chemotherapy in ypStage II patients. First, neoadjuvant chemoradiation may lead to downstaging, and a portion of ypStage II patients might be pN^+ before receiving neoadjuvant treatment. In addition, patients with ypStage II mainly had T3–T4 stage cancer, which might infiltrate deeper before neoadjuvant treatment was received. Therefore, the adjuvant chemotherapy regimens guided by ypTNM stage after neoadjuvant chemoradiation may be different from those administered according to pTNM stage without neoadjuvant chemoradiation. Therefore, these reasons may plausibly explain the improved survival in ypStage II patients, which was different from that in pStage II patients. Studies that explore the efficacy of adjuvant chemotherapy following neoadjuvant treatment according to ypStage are needed for further validation.

Oxaliplatin-based adjuvant chemotherapy was provided for patients with LARC after neoadjuvant treatment and surgery. However, in our analysis, adding oxaliplatin to adjuvant chemotherapy did not confer a benefit in either OS or DFS. This result might have been due to the toxicity of oxaliplatin causing a dose reduction-a factor that would negatively affect survival. In some studies [4, 11, 15, 29], oxaliplatin was added to neoadjuvant treatment in the OX/FU-based group. The toxicity of oxaliplatin had cumulative effects, and using oxaliplatin-based adjuvant chemotherapy after oxaliplatin-based neoadjuvant treatment increased the toxicity, thereby affecting the efficacy of adjuvant chemotherapy [11]. Our results showed that oxaliplatin could lead to toxicity, which was clearly reflected by neuropathy, acute reaction, vomiting, and nausea. These side effects may decrease patient compliance. In the ADORE trial, cycles with reduced doses were more frequent in the OX/FU-based group than in the FU-based group [12]. Our meta-analysis indicated no significant difference in compliance in the completion rate of the planned cycles between the two groups, but dose reduction decreased the efficacy of adjuvant chemotherapy. Therefore, the decision to add oxaliplatin in adjuvant chemotherapy should account for the balance between efficacy and toxicity. Finally, a study has found that adding oxaliplatin is not associated with OS or DFS in patients ≥73 years of age [37]. Therefore, in this study, some patients were above 73 years old, thus, possibly affecting the final results. However, we did not discuss this possibility further because of a lack of data.

In clinical practice, evaluating the effects of neoadjuvant treatment strategy on the survival benefits of adjuvant treatment in patients with LARC is meaningful. Given that most of the included studies used neoadjuvant long-course chemoradiation, we further evaluated the survival benefits of adjuvant chemotherapy in the setting of neoadjuvant long-course chemoradiation. The results showed similar results to those of the overall analysis, indicating that adjuvant chemotherapy, compared with observation, contributes to survival benefit, and that adding oxaliplatin to FU-based adjuvant chemotherapy does not contribute to survival benefits beyond those conferred by FU-based adjuvant chemotherapy. In terms of neoadjuvant chemotherapy strategy, further subgroup analyses were conducted to evaluate the effects of neoadjuvant long-course chemoradiation with preoperative FU-based chemotherapy or neoadjuvant long-course chemoradiation with preoperative OX/FU-based chemotherapy on survival outcomes. Similar results were observed, thus, demonstrating the reliability and accuracy of our results. However, subgroup analysis based on preoperative radiotherapy strategy (short-course versus long-course radiotherapy) could not be conducted, owing to an insufficient number of studies. Thus, future large-scale, prospective clinical studies are needed to explore the influence of neoadjuvant treatment strategy, including preoperative short-course radiotherapy, preoperative long-course radiotherapy, and long-course chemoradiation, on the relationship between adjuvant chemotherapy and survival benefits. Such
an understanding may lead to more effective and suitable clinical treatment strategies for patients with LARC.

There are several limitations to the current research. First, this was a retrospective analysis, and the potential for confounding on the basis of patient selection could not be eliminated. Second, we were unable to obtain the personal details of patients, although this information might have enabled better control of the confounding factors. Third, the heterogeneity in the study that could not be eliminated by subgroup analysis might have affected external authenticity to some extent. Moreover, some patients may have better pathological responses to neoadjuvant treatment, thus, achieving ypStage1 or even ypStage 0 after neoadjuvant treatment; however, the survival benefit of adjuvant chemotherapy still remains unclear for these patients in clinical practice. Unfortunately, we could not perform further analysis because the data for patients with ypStage 0 or I after neoadjuvant treatment were insufficient. In addition, we were unable to perform more subgroup analyses because of the insufficient number of studies. Finally, the recent guidelines for adjuvant chemotherapy regimens are mainly based on pStage. Differences exist between ypStage and pStage, and, thus, chemotherapy guided by ypStage might require further exploration. Future studies are needed to further investigate and resolve these problems.

5. Conclusions

Compared with observation, adjuvant chemotherapy was found to prolong OS in patients with LARC after neoadjuvant (chemo) radiotherapy and curative surgery. However, no survival benefit was observed with the addition of oxaliplatin to FU-based adjuvant chemotherapy compared with FU-based adjuvant chemotherapy.

Data Availability

The research data used to support the findings of this study were supplied by Zhenning Wang under license and so cannot be made freely available. Requests for access to these data should be made to Zhenning Wang, E-mail: josieon826@sina.cn.

Ethical Approval

The study did not violate the local regulations and was approved by the Research Ethics Committee of China Medical University, China.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

Jia-yi Li and Xuan-zhang Huang contributed equally to this work.

Acknowledgments

We thank the Department of Surgical Oncology of First Hospital of China Medical University for technical assistance. The corresponding author had full access to all the data and analyses. This work was supported by the National Key R&D Program of China (MOST-2017YFC0908300), Technological Special Project of Liaoning Province of China (2019020176-JH1/103), Natural Science Foundation of Liaoning Province of China (2019-MS-390), China Postdoctoral Science Foundation Grant (2018M641746), and The Natural Science Foundation Medical and Health Joint Fund Project of Liaoning Province (20180530006).

Supplementary Materials

Supplementary File 1: PRISMA checklist. Supplementary File 2: detailed search strategy and result for each database. (Supplementary Materials)

References

[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[2] "Rectal Cancer Version 1.2021. NCCN clinical practice guidelines in oncology," 2021, https://www.nccn.org/professionals/physician_gls/default.aspx#rectal.
[3] R. Glynn-Jones, L. Wyrwicz, E. Tiret et al., “Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up”, Annals of Oncology, vol. 28, suppl_4, pp. -iv22–iv40, 2017.
[4] K. Y. You, R. Huang, P. R. Ding et al., “Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0," International journal of colorectal disease, vol. 29, no. 4, pp. 529–538, 2014.
[5] Z. Sun, B. Gilmore, M. A. Adam et al., “Adjuvant chemotherapy after preoperative chemoradiation improves survival in patients with locally advanced rectal cancer," Diseases of the Colon and Rectum, vol. 60, no. 10, pp. 1050–1056, 2017.
[6] A. S. Kulaylat, C. S. Hollenbeak, and D. B. Stewart Sr., “Adjuvant chemotherapy improves overall survival of rectal cancer patients treated with neoadjuvant chemoradiotherapy regardless of pathologic nodal status," Annals of Surgical Oncology, vol. 24, no. 5, pp. 1281–1288, 2017.
[7] J. V. Gahagan, M. D. Whealon, M. J. Phelan et al., “Improved survival with adjuvant chemotherapy in locally advanced rectal cancer patients treated with preoperative chemoradiation regardless of pathologic response," Surgical Oncology, vol. 32, pp. 35–40, 2020.
[8] D. H. Ahn, C. Wu, L. Wei et al., “The efficacy of adjuvant chemotherapy in patients with stage II/III resected rectal cancer treated with neoadjuvant chemoradiation therapy," American Journal of Clinical Oncology, vol. 40, no. 6, pp. 531–534, 2017.
[9] T. André, C. Boni, L. Mounedji-Boudiaf et al., “Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer," The New England Journal of Medicine, vol. 350, no. 23, pp. 2343–2351, 2004.
[10] J. P. Kuebler, H. S. Wieand, M. J. O’Connell et al., “Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07,” *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, vol. 25, no. 16, pp. 2198–2204, 2007.

[11] C. Rödel, U. Graeven, R. Fietkau et al., “Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial,” *The Lancet Oncology*, vol. 16, no. 8, pp. 979–989, 2015.

[12] Y. S. Hong, S. Y. Kim, J. S. Lee et al., “Oxaliplatin-based adjuvant chemotherapy for rectal cancer after preoperative chemoradiotherapy (ADORE): long-term results of a randomized controlled trial,” *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, vol. 37, no. 33, pp. 3111–3123, 2019.

[13] R. D. Hoheinz, H. J. Schmoll, K. Haustermans et al., “Final results of PETACC-6: preoperative chemoradiotherapy and postoperative chemotherapy with capcitabine +/-oxaliplatin in locally advanced rectal cancer,” *Oncology Research and Treatment*, vol. 41, Supplement 4, p. 123, 2018.

[14] R. Glynne-Jones, N. Counsell, P. Quirk et al., “Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capcitabine plus oxaliplatin (XELOX) versus control,” *Annals of Oncology : official Journal of the European Society for Medical Oncology*, vol. 25, no. 7, pp. 1356–1362, 2014.

[15] J. H. Peng, J. Z. Lin, Y. M. Rong et al., “Oxaliplatin-containing adjuvant chemotherapy improves the survival of locally advanced rectal cancer patients with pathological complete response after pre-operative chemoradiotherapy,” *Gastroenterology Report*, vol. 6, no. 3, pp. 195–201, 2018.

[16] R. Geva, E. Itzkovich, S. Shami et al., “Is there a role for adjuvant chemotherapy in pathological complete response rectal cancer tumors following neoadjuvant chemoradiation?,” *Journal of Cancer Research and Clinical Oncology*, vol. 140, no. 9, pp. 1489–1494, 2014.

[17] P. Gao, Y. X. Song, J. X. Sun et al., “Which is the best postoperative chemotherapy regimen in patients with rectal cancer after neoadjuvant therapy?,” *BMC Cancer*, vol. 14, no. 1, p. 888, 2014.

[18] C. Galata, K. Merx, S. Mai et al., “Impact of adjuvant chemotherapy on patients with ypT0-2 ypN0 rectal cancer after neoadjuvant chemoradiation: a cohort study from a tertiary referral hospital,” *World Journal of Surgical Oncology*, vol. 16, no. 1, p. 156, 2018.

[19] Y. T. Liao, Y. L. Lin, J. Huang, J. S. Hung, and B. R. Lin, “Downstaged ypT0-2N0 rectal cancer after neoadjuvant chemoradiation therapy may not need adjuvant chemotherapy: a retrospective cohort study,” *International Journal of Colorectal Disease*, vol. 36, no. 3, pp. 509–516, 2021.

[20] Z. Lu, P. Cheng, M. G. Zhang, X. S. Wang, and Z. X. Zheng, “Is adjuvant chemotherapy necessary for patients with ypT0-2N0 rectal cancer treated with neoadjuvant chemoradiotherapy and curative surgery?,” *Gastroenterology Report*, vol. 6, no. 4, pp. 277–283, 2018.

[21] D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and The PRISMA Group, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” *PLoS Medicine*, vol. 6, no. 7, article e100097, 2009.

[22] A. Stang, “Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses,” *European Journal of Epidemiology*, vol. 25, no. 9, pp. 603–605, 2010.

[23] J. F. Tierney, L. A. Stewart, D. G. Gherzi, S. Burdett, and M. R. Sydes, “Practical methods for incorporating summary time-to-event data into meta-analysis,” *Trials*, vol. 8, no. 1, p. 16, 2007.

[24] J. P. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” *BMJ*, vol. 327, no. 7414, pp. 557–560, 2003.

[25] C. B. Begg and M. Mazumdar, “Operating characteristics of a rank correlation test for publication bias,” *Biometrics*, vol. 50, no. 4, pp. 1088–1101, 1994.

[26] M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” *BMJ*, vol. 315, no. 7109, pp. 629–634, 1997.

[27] J. Sastre, J. J. Serrano, C. Fernández et al., “Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series,” *Clinical Colorectal Cancer*, vol. 15, no. 2, pp. 128–134, 2016.

[28] M. J. Chung, J. H. Lee, J. H. Lee et al., “Adjuvant chemotherapy in rectal cancer patients treated with preoperative chemoradiation and total mesorectal excision: a multicenter and retrospective propensity-score matching study,” *International Journal of Radiation Oncology • Biology • Physics*, vol. 103, no. 2, pp. 438–448, 2019.

[29] J. M. Loree, H. F. Kennecke, R. M. Lee-Ying et al., “Impact of postoperative adjuvant chemotherapy following long-course chemoradiotherapy in stage II rectal cancer,” *American Journal of Clinical Oncology*, vol. 41, no. 7, pp. 643–648, 2018.

[30] B. Garlipp, H. Ptok, F. Benedix et al., “Adjuvant treatment for resected rectal cancer: impact of standard and intensified postoperative chemotherapy on disease-free survival in patients undergoing preoperative chemoradiation—a propensity score-matched analysis of an observational database,” *Langenbeck’s Archives of Surgery*, vol. 401, no. 8, pp. 1179–1190, 2016.

[31] A. Sainato, V. Cernusco Luna Nunzia, V. Valentini et al., “No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT),” *Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology*, vol. 113, no. 2, pp. 223–229, 2014.

[32] F. C. Kuan, C. H. Lai, H. Y. Ku et al., “The survival impact of delayed surgery and adjuvant chemotherapy on stage II/III rectal cancer with pathological complete response after neoadjuvant chemoradiation,” *International Journal of Cancer*, vol. 140, no. 7, pp. 1662–1669, 2017.

[33] R. P. Kiran, H. T. Kirat, A. N. Burgess, P. J. Nisar, M. F. Kalady, and J. C. Lavery, “Is adjuvant chemotherapy really needed after curative surgery for rectal cancer patients who are node-negative after neoadjuvant chemoradiotherapy?,” *Annals of Surgical Oncology*, vol. 19, no. 4, pp. 1206–1212, 2012.

[34] K. U. Jung, H. C. Kim, J. O. Park et al., “Adjuvant chemotherapy after neoadjuvant chemoradiation and curative resection for rectal cancer: is it necessary for all patients?,” *Journal of Surgical Oncology*, vol. 111, no. 4, pp. 439–444, 2015.

[35] A. J. Breugom, W. van Gijn, E. W. Muller et al., “Adjuvant chemotherapy for rectal cancer patients treated with preoperative...
(chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial,” *Annals of Oncology*, vol. 26, no. 4, pp. 696–701, 2015.

[36] J. F. Bosset, G. Calais, L. Mineur et al., “Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study,” *The Lancet Oncology*, vol. 15, no. 2, pp. 184–190, 2014.

[37] X. Z. Huang, P. Gao, Y. X. Song et al., “Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy,” *Oncotarget*, vol. 7, no. 15, pp. 19643–19653, 2016.